HOME >> BIOLOGY >> NEWS
Science highlights of AAN Annual Meeting in Honolulu March 29 April 5

MRI scans show "silent strokes" and loss of brain volume.

Homocysteine can be reduced by certain vitamins. Whether vitamin therapy can reduce the risk for a second stroke was addressed by a large consortium led by researchers at Wake Forest University School of Medicine in Winston-Salem, North Carolina. They found that while high doses of vitamins B6, B12, and folic acid could reduce homocysteine consistently, stroke risk was not reduced compared to low-dose vitamins, which had no effect on homocysteine concentrations. These results suggest either that more dramatic homocysteine reductions are needed, or that other strategies must be used to reduce the risk of a second stroke.

Sleep apnea, or breathing difficulty, affects half of all stroke victims. Researchers from Zurich showed that stroke patients with sleep apnea have a greater risk of worsening of the effects of their stroke, suggesting that treatment of sleep apnea in these patients may be beneficial.

Finally, researchers at the University of Chicago and Arizona State University compared brain activation of amateur and professional golfers as they visualized performing their swing. Much smaller areas of the brain were activated by the highly trained professionals, and some structures active in the amateurs were entirely silent in the professionals. Not only do these results shed light on the neurological effects of training, they also indicate that post-stroke movement rehabilitation should be tailored to an individuals previous level of training and expertise in a particular movement.


'"/>

Contact: Marilee Reu
mreu@aan.com
651-695-2789
American Academy of Neurology
14-Apr-2003


Page: 1 2 3 4

Related biology news :

1. A long-necked sea predator from China described in Science
2. Brown ecologist garners major National Science Foundation grant
3. Popular Science announces Third Annual Brilliant 10
4. Winner of 2004 EMBO Science Writing Prize announced
5. Study in Science reveals recreational fishing takes big bite of ocean catch
6. New paper in Science introduces revolutionary new paradigm for fishery management
7. Articles on forest fire risks published in BioScience
8. Ralph J. Cicerone nominated to be next National Academy of Sciences president
9. Canine word-learning research published in Science
10. Articles on remote sensing in ecology published in BioScience
11. Fostering Diversity in the Sciences Symposium

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Science highlights AAN Annual Meeting Honolulu March April

(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... Research and Markets , ... http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of the ... to their offering. One major ... of multimodal biometric systems. Multimodal biometric systems utilize ... verification and identification purposes. This helps to reduce ...
(Date:12/10/2014)... Dec. 9, 2014  Wake Forest Baptist Medical Center today ... its School of Medicine. Funding for this $50 million ... that will be publicly launched next summer. ... the former 60 series R.J. Reynolds Tobacco Company complex, ... will begin immediately with plans to be ready to ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
(Date:12/19/2014)... The empty capsules market is experiencing growth ... technological innovations in the empty capsules market. The ... growth of the empty capsules market. , Get ... of Report , The report will enrich both ... to gauge the pulse of the market which ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... December 17, 2014 Ipsen Biopharmaceuticals, ... IPN; ADR: IPSEY), today announced that ... as Somatuline®) was approved by the U.S. Food ... gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with ... metastatic disease to improve progression-free survival (PFS). , ...
(Date:12/17/2014)... Audacity, a leading California-based health and science ... Huntsworth Health Group, is proud to announce the addition ... role, Gonzales will serve as Senior Vice President of ... welcome a talent of Jamie’s caliber to the Audacity ... is a proven healthcare innovation leader and brand management ...
Breaking Biology Technology:Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2
Cached News: